Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership ...

Telecom Italia (TIM) on Wednesday posted a 5.4% rise in its core earnings in the first quarter but debt at Italy's biggest telecoms group edged up as cash generation was negative in the period.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...

European markets closed lower on Wednesday, with traders monitoring corporate earnings and awaiting the Federal Reserve’s ...